PLXNA2

Across TCGA pan-cancer cohorts, PLXNA2 mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated PLXNA2 data layer compared with 23 for mass-spec protein and 12 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher PLXNA2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated PLXNA2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and GBM show a favorable association.

UCEC, GBM, and LUAD are the cancer types where PLXNA2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Quartile	II,III,IV	1.000	0.471	.018	6	view →
GBM	DFS	Quartile	All	0.948	0.639	.001	4	view →
LUAD	OS	Tertile	All	0.881	0.672	.031	4	view →
PDAC	OS	Tertile	III,IV	0.576	0.282	.023	4	view →
CCRCC	OS	Median	IV	0.789	0.109	.036	3	view →
HNSC	OS	Quartile	II,III,IV	0.925	1.000	.033	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

PLXNA2–UCEC (DFS)

Open the UCEC breakdown →